Diabetes and Diabetic Complications: Major World Markets, 3rd Ed.

Table of Contents

chapter one: Executive Summary

• Background
• Scope and Methodology
• Size and Growth of Market
• The Nature of the Industry
• The New Technologies
• Market Trends

chapter two: Introduction

• Background
• The Pathology of Diabetes and Its Complications
  • Diabetes
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
  • Long-Term Complications of Diabetes
  • Hypertension
  • Dyslipidemia
  • Cardiovascular Disease
  • Vascular Complications
  • Diabetic Retinopathy
  • Renal Complications
  • Neuropathies
  • Diabetic Foot
• Epidemiology
  • France
  • Germany
  • Italy
  • Japan
  • Spain
  • United Kingdom
  • United States

chapter three: Diabetes Monitoring

• Background
• Glucose Monitoring
  • Background and History
  • Urine Testing
  • Blood Testing
  • Colorimetric Monitors
  • Modern Glucose Monitors
  • Leading Products
  • Features and Marketing Approach
  • Noninvasive Techniques
  • Near Infrared (NIR) Spectroscopy
  • Mid-Infrared Absorption/Emission
  • Stimulated Emissions (Raman or Fluorescence)
  • Terahertz Spectroscopy
  • Photoacoustic Spectroscopy
  • Optical Rotation
  • Optical Rotation in Tissue
  • Light Scattering
  • Transdermal Techniques (Trans-Membrane) Techniques
  • Subdermal Techniques
• Hemoglobin A1C (HbA1C)
  • Background
  • Standardization Issues
  • Levels and Goals
  • Products
• Ketone Monitoring
• Microalbumin Monitoring

chapter four: Current Therapeutic Approaches

• Background
• Therapeutic Practices
  • France
    • Diabetes
    • Complication: Hypertension
    • Complication: Dyslipidemia
    • Complication: Atherosclerosis
    • Complication: Arrhythmias
    • Complication: Peripheral Vascular Disease
  • Germany
    • Diabetes
    • Complication: Hypertension
    • Complication: Dyslipidemia
    • Complication: Atherosclerosis
    • Complication: Arrhythmias
    • Complication: Peripheral Vascular Disease
  • Italy
    • Diabetes
    • Complication: Hypertension
    • Complication: Dyslipidemia
    • Complication: Atherosclerosis
    • Complication: Arrhythmias
    • Complication: Peripheral Vascular Disease
  • Japan
    • Diabetes
    • Complication: Hypertension
    • Complication: Dyslipidemia
    • Complication: Atherosclerosis
    • Complication: Arrhythmias
    • Complication: Peripheral Vascular Disease
  • Spain
    • Diabetes
    • Complication: Hypertension
    • Complication: Dyslipidemia
    • Complication: Atherosclerosis
    • Complication: Arrhythmias
    • Complication: Peripheral Vascular Disease
  • United Kingdom
    • Diabetes
    • Complication: Hypertension
    • Complication: Dyslipidemia
    • Complication: Atherosclerosis
    • Complication: Arrhythmias
    • Complication: Peripheral Vascular Disease
  • United States
    • Diabetes
    • Complication: Hypertension
    • Complication: Dyslipidemia
    • Complication: Atherosclerosis
    • Complication: Arrhythmias
    • Complication: Peripheral Vascular Disease
• Current Therapeutics for Diabetes
  • Insulin
    • Regular Insulin
    • Long-Acting and Basal Insulin
    • Rapidly Acting Insulin
    • Combinations
    • Insulin Pumps
    • Insulin Pens
    • Inhaled Insulin
    • Other Treatments
  • Oral Hypoglycemics
    • Sulfonylureas
    • Biguanides
    • á-Glucosidase Inhibitors
    • Thiazolidinediones
    • Meglitinides
    • D-Phenylalanine Derivatives
    • Peptide Amides
  • Current Therapeutics for Diabetic Complications
    • Antihypertensive Therapy
      • ACE Inhibitors
      • á/â(Alpha/Beta)-Blockers
      • Calcium Channel Blockers
      • Diuretics
      • Angiotensin II Receptor Antagonists
    • Dyslipidemia Therapy
      • HMG-CoA Reductase Inhibitors--Statins
      • Bile Acid Sequestrants
      • Fibric Acid Derivatives
      • Niacin
      • Cholesterol Absorption Inhibitors
    • Atherosclerosis Therapy
    • Arrhythmia Therapy
    • Peripheral Vascular Disease Therapy

Chapter five: Diabetes Monitoring and Therapeutics Markets

• Background
• Market Status and Segmentation
  • Diabetes Monitoring
  • Blood Ketones
  • Microalbumin
  • Blood Glucose
  • Geographic Variation
• Therapeutics
  • Insulin
  • Oral Hypoglycemics
  • Diabetic Complication Drugs
• Market Trends in Geographic Markets
  • France
  • Germany
  • Italy
  • Japan
  • Spain
  • United Kingdom
  • United States

chapter six: Nutritional Supplement and Herbal Approaches to the Treatment of Diabetes

• Background
• Nutritional Supplements
  • Ascorbic Acid (Vitamin C)
  • Biotin
  • Chromium
  • Copper
  • Magnesium
  • Niacin and Niacinamide
  • Potassium
  • Selenium
  • Thiamine
  • Vanadium
  • Vitamin B6 (Pyridoxine)
  • Vitamin B12
  • Vitamin E
  • Zinc
  • Nutritional Treatment of Diabetic Neuropathy
• Herbal Treatment of Diabetes
  • Aloe (Various)
  • Arctium lappa (Burdock Root)
  • Allium cepa (Onion)
  • Grifola frondosa (Maitake Mushroom)
  • Mulberry
  • Panax ginseng (Korean ginseng)
• Ayurvedic Medicine and Herbs
  • Gymnema sylvestre (Asclepias germinata)
  • Momordica charantia (Bitter Gourd)
  • Trigonella foenum graecum (Fenugreek)
• Other Herbs with Significant Anti-Diabetic Effects
• Traditional Chinese Medicine

chapter seven: Forward Looking Technologies

• New Products and the Development Pipeline
• â-Cell Transplantation Research

chapter eight: Company Profiles

• Abbott Laboratories
• Amylin Pharmaceuticals
• AstraZeneca
• Bayer Healthcare Diabetes Care
• GlaxoSmithKline
• Eli Lilly & Co.
• Metabolex, Inc.
• Novo Nordisk A/S
• Pfizer Inc.
• Sanofi-Aventis US

chapter nine: Conclusions and Strategic Implications

• First Conclusion
• Implications:
• Second Conclusion
• Implications:
• Third Conclusion
• Implications:
• Fourth Conclusion
• Implications:
• Fifth Conclusion
• Implications:
• Sixth Conclusion
• Implications:
• Seventh Conclusion
• Implications:
• Eighth Conclusion
• Implications:
• Ninth Conclusion
• Implications:
• Tenth Conclusion
• Implications:
• Eleventh Conclusion
• Implications:
• Twelfth Conclusion
• Implications:
• Thirteenth Conclusion
• Implications:
• Fifteenth Conclusion
• Implications:
• Sixteenth Conclusion
• Implications:
• Seventeenth Conclusion
• Implications:

Appendix A:GLOSSARY

Appendix B: Company Directory

List of Exhibits

chapter one: Executive Summary

• Figure 1-1: Diagnosed Diabetes Cases in the Seven Major World Healthcare Markets: 2004 - 2014
• Figure 1-2: Trending in the Market Potential in the World' s Major Blood Glucose Monitoring Markets 2006 - 2016
• Table 1-1: Estimated Market Potential for Insulin in the Seven Major World Healthcare Markets 2006 - 2016
• Table 1-2: Estimated Market Potential for Oral Hypoglycemics in the Seven Major World Healthcare Markets 2006 - 2016
• Table 1-3: Estimated Market Sizes for Drugs to Treat Diabetic Complications in the Seven Major World Healthcare Markets by Complication (Hypertension, Dyslipidemia, Arrhythmias, Peripheral Vascular Disease) 2006 - 2016

chapter two: Introduction

• Table 2-1: Characteristics of Type I and Type II Diabetes Mellitus
• Table 2-2: Common Symptoms and Conditions of Diabetes Mellitus
• Table 2-3: Populations of Each of the Seven Major Healthcare Markets 2006-2016
• Table 2-4: Populations of Each of the Seven Major World Healthcare Markets by Age Group (0-14, 15-64, 65+ Years) 2006
• Table 2-5: Prevalence Rates and Cases for Diabetes Mellitus by Type (Type I vs Type II) in Each of the Seven Major World Healthcare Markets 2006
• Table 2-6: Prevalence of Diabetes in the Seven Major World Healthcare Markets by Type (I vs II) 2004-2014
• Figure 2-1: Trending in the Total Prevalence of Diabetes Cases and the General Population in the Seven Major World Healthcare Markets 2006 - 2016
• Figure 2-2: Composition of the Diabetes Patient Population in the Seven Major World Healthcare Markets 2006-2016
• Figure 2-3: Geographic Distribution of the Total Diabetes Patient Population 2006 and 2016
• Figure 2-4: Geographic Distribution of the Type 1 Diabetes Patient Population 2006 and 2016
• Figure 2-5: Geographic Distribution of the Type 2 Diabetes Patient Population 2006 and 2016
• Figure 2-6: Population Trends in the Seven Major World Healthcare Markets: 2006-2016
• Figure 2-7: The Prevalence of Diabetes in France: 2006 - 2016
• Figure 2-8: The Prevalence of Diabetes in Germany: 2006 - 2016
• Figure 2-9: The Prevalence of Diabetes in Italy: 2006 - 2016
• Figure 2-10: The Prevalence of Diabetes in Japan: 2006 - 2016
• Figure 2-11: The Prevalence of Diabetes in Spain: 2006 - 2016
• Figure 2-12: The Prevalence of Diabetes in the United Kingdom: 2006 - 2016
• Figure 2-13: The Prevalence of Diabetes in the United States: 2006 - 2016

chapter three: Diabetes Monitoring

• Table 3-1: Key Glucose Monitoring Products on the Market
• Table 3-2: Twenty-Five Year Historic Record of Glucose Monitors Approved by the U.S. Food and Drug Administration (Product, Company, Approval Date)
• Table 3-3: Key HbA1C Monitors and Test Kit Services (Company, Product, Description)
• Table 3-4: Key Ketone Monitoring Products on the Market (Company, Product, Description)
• Table 3-5: Key Microalbumin Monitoring Products on the Market (Company, Product, Description)

chapter four: Current Therapeutic Approaches

• Table 4-1: Estimated Number of Preventable Diabetes Cases and Complications in the United States
• Table 4-2: Key Insulin Products for the Treatment of Diabetes (Brand, Insulin Type, Manufactuer/Marketer)
• Table 4-3: Key Oral Hypoglycemics for the Treatment of Type II Diabetes (Brand, Compound, Manufacturer/Marketer, Class)
• Table 4-4: Common ACE Inhibitors on the Market for Diabetic Hypertension (Brand, Compound, Manufacturer/Marketer)
• Table 4-5: Common Adrenergic Receptors (á and â) on the Market for Diabetic Hypertension (Brand Name, Compound, Manufacturer/ Marketer, Receptor Type)
• Table 4-6: Common Calcium Channel Blockers and Combinations on the Market for Diabetic Hypertension (Brand Name, Compound, Manufacturer/Marketer)
• Table 4-7: Common Diuretic Products and Diuretic Combinations on the Market for Diabetic Hypertension (Brand, Compounds, Manufacturer/Marketer, Class)
• Table 4-8: Common Angiotensin II Receptor Antagonists on the Market for Diabetic Hypertension ((Brand, Compound, Manufacturer/ Marketer)
• Table 4-9: Commonly Used Antilipemic Agents on the Market for Diabetic Dyslipidemia (Brand, Compounds, Manufacturer/Marketer, Class)
• Table 4-10: Vaughn Williams Classification of Anti-Arrhythmic Drugs
• Table 4-11: Common Antiarrhythmatic Drugs (Brand, Compound, Manufacturer/Marketer, Group)
• Table 4-12: Drugs Commonly Used to Combat Diabetic Peripheral Vascular Disease (Brand, Compound, Manufacturer/Marketer, Type)

Chapter five: Diabetes Monitoring and Therapeutics Markets

• Table 5-1: Estimated Market Sizes for Blood Glucose Monitoring Equipment and Supplies in the Seven Major World Healthcare Markets by Country 2006-2016
• Figure 5-1: Trending in the World' s Major Blood Glucose Monitoring Markets (Total): 2006 - 2016
• Figure 5-2: Distribution of the World' s Major Blood Glucose Monitoring Markets by Country: 2006 / 2011 / 20016
• Figure 5-3: Estimated Market Shares of the Key Participants in the Seven Major World' s Markets for Glucose Monitoring Products: 2006
• Table 5-2: Estimated Market Sizes for Insulin in the Seven Major World Healthcare Markets by Country 2006 - 2016
• Figure 5-4: Trending in the World' s Major Markets for Insulin: 2006 - 2016
• Figure 5-5: Market Distribution in the World' s Major Markets for Insulin 2006 - 2016
• Figure 5-6: Estimated Insulin Market Shares in the Seven Major World Healthcare Markets: 2006
• Table 5-3: Estimated Market Sizes for Oral Hypoglycemics in the Seven Major World Healthcare Markets by Country 2006 - 2016
• Figure 5-7: Trending in the World' s Major Markets for Oral Hypoglycemic Drugs: 2006 - 2016
• Figure 5-8: Market Distribution in the World' s Major Markets for Oral Hypoglycemics: 2006 - 2016
• Figure 5-9: Estimated Oral Hypoglycemic Drug Market Shares in the Seven Major World Healthcare Markets: 2006
• Table 5-4: Estimated Market Sizes for Drugs to Treat Diabetic Complications in the Seven Major World Healthcare Markets by Drug Type (Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmia Drugs, Peripheral Vascular Disease Drugs) 2016-2016
• Figure 5-10: Trending in the Total World' s Major Markets for Drugs to Treat Diabetic Complications (By Complication): 2006 - 2016
• Figure 5-11: Composition of the Total World' s Major Markets for Drugs to Treat Diabetic Complications (by Complication): 2006 - 2016
• Table 5-5: Estimated Diabetes-Care Market Size in France by Segment (Blood Glucose Monitoring, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs) 2006 - 2016
• Figure 5-12: Trending in the French Market for Diabetes-Care Products Product Class: 2006 - 2016
• Figure 5-13: Composition of the French Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Table 5-6: Estimated Diabetes-Care Market Size in Germany: by Segment (Blood Glucose Monitoring, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs) 2006 - 2016
• Figure 5-14: Trending in the German Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Figure 5-15: Composition of the German Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Table 5-7: Estimated Diabetes-Care Market Size in Italy by Segment (Blood Glucose Monitoring, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs), 2006 - 2016
• Figure 5-16: Trending in the Italian Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Figure 5-17: Composition of the Italian Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Table 5-8: Estimated Diabetes-Care Market Size in Japan by Segment (Blood Glucose Monitoring, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs), 2006 - 2016
• Figure 5-18: Trending in the Japanese Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Figure 5-19: Composition of the Japanese Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Table 5-9: Estimated Diabetes-Care Market Size in Spain: by Segment (Blood Glucose Monitoring, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs), 2006 - 2016
• Figure 5-20: Trending in the Spanish Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Figure 5-21: Composition of the Spanish Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Table 5-10: Estimated Diabetes-Care Market Size in the United Kingdom by Segment (Blood Glucose Monitoring, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs), 2006 - 2016
• Figure 5-22: Trending in the United Kingdom Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Figure 5-23: Composition of the United Kingdom Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Table 5-11: Estimated Diabetes-Care Market Size in the United States: by Segment (Blood Glucose Monitoring, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs), 2006 - 2016
• Figure 5-24: Trending in the United States Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Figure 5-25: Composition of the United States Market for Diabetes-Care Products by Product Class: 2006 - 2016

chapter seven: Forward Looking Technologies

• Table 7-1: Recently Introduced or Diabetes-Designated Products (Product, Generic Name, Company, Diabetes Type, Introduction/Approval Date)
• Table 7-2: Products in Development for Diabetes and Diabetic Complications (Brand Name, Generic Name, Indications, Company, Development Status)